Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582798 | 1.00 | MIF (0.47) | MIFCYP19A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29953520 | 0.88 | MAOA (0.47) | CYP19A1ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL6832547 | 0.88 | MAOA (0.47) | CYP19A1ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL316466 | 0.83 | CYP26A1 (0.48) | MIFCYP19A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL25314366 | 0.83 | MAPT (0.41) | MIFALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL30707980 | 0.83 | MAPT (0.41) | MIFALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL10470879 | 0.79 | MIF (0.48) | MIFCYP19A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15333322 | 0.78 | PDE4D (0.43) | CYP19A1ALDH1A1MAPTCYP11B2KDM4E | |
| SCHEMBL29582422 | 0.78 | MAOB (0.46) | MIFCYP19A1CYP26A1 | |
| SCHEMBL449192 | 0.78 | MAOB (0.46) | MIFCYP19A1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522554-B2 | Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist | LG CHEM, LTD. (KR) | 2026-01-13 | — | — | US | disclosed |
| US-20240217935-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217935-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-4306513-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Lg Chem, Ltd. (KR) | 2024-01-17 | — | — | EP | disclosed |
| US-20240002322-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-01-04 | — | — | US | disclosed |
| CN-117242057-A | Process for preparing intermediates useful in the synthesis of sphingosine-1-phosphate receptor agonists | 株式会社LG化学 | 2023-12-15 | — | — | CN | disclosed |
| CN-117203189-A | Process for preparing intermediates useful in the synthesis of sphingosine-1-phosphate receptor agonists | 株式会社LG化学 | 2023-12-08 | — | — | CN | disclosed |
| CN-117136183-A | Novel process for preparing sphingosine-1-phosphate receptor agonists | 株式会社LG化学 | 2023-11-28 | — | — | CN | disclosed |
| CN-117136181-A | Preparation method of intermediate for synthesizing sphingosine-1-phosphate receptor agonist | 株式会社LG化学 | 2023-11-28 | — | — | CN | disclosed |
| EP-4219443-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Lg Chem, Ltd. (KR) | 2023-08-02 | — | — | EP | disclosed |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-2342189-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF OSTEOARTHRITIS | ELI LILLY AND COMPANY (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010036497-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ELI LILLY AND COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036497-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ELI LILLY AND COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | S1PR1, S1PR3, EDNRA | MIF 1221/4885CYP19A1 1167/4885ALDH1A1 2245/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | MIF 1315/4885CYP19A1 1113/4885ALDH1A1 2082/4885 |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ESRRA, GPER1, ESR2 | MIF 1362/4885CYP19A1 9/4885ALDH1A1 405/4885 |
| US-20240002322-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | S1PR5, S1PR1, S1PR3 | MIF 4673/4885CYP19A1 1411/4885ALDH1A1 1426/4885 |
| US-20240217935-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | S1PR4, S1PR1, S1PR3 | MIF 4576/4885CYP19A1 1515/4885ALDH1A1 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.